845264-92-8
845264-92-8 structure
- Name: Atacicept
- Chemical Name: Atacicept
- CAS Number: 845264-92-8
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2019-01-15 13:15:14
- Modify Date: 2024-01-08 18:20:59
-
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease[1][2].
| Name | Atacicept |
|---|
| Description | Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Atacicept (TACI-Ig; 100 μg; i.p.; three times of week for 14 days; BALB/c mice) reduces mature B-cell counts and serum antibody levels in normal mice[1]. Atacicept (TACI-Ig) inhibits the progression of disease and autoantibody titers in a mouse model of collagen-induced arthritis (CIA)[1]. Animal Model: Male DBA/1 mice with CIA models[1] Dosage: 100 μg Administration: intraperitoneal injection; three times of week for 21 days Result: Increased serum titers of anti-collagen Abs and few overt signs of disease. Animal Model: BALB/c mice[1] Dosage: 100 μg Administration: intraperitoneal injection; three times of week for 14 days Result: Reduced mature B cell populations but had little effect on other cell lineages. Blocked the development of B cells at the transition from T1 to T2 and the development of MZ B cells in the spleen. Decerased the serum levels of IgM about 2.3-fold. |
| References |
| No Any Chemical & Physical Properties |